Yusuf Yilmaz

List of Publications by Year
in descending order

119 papers	11,217 citations	81900 39 h-index	32842 100 g-index
120 all docs	120 docs citations	120 times ranked	10122 citing authors

#	Article	IF	Citations
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
3	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2672-2682.	7.3	1,203
4	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clinical Gastroenterology and Hepatology, 2019, 17, 748-755.e3.	4.4	559
5	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine, 2014, 11, e1001680.	8.4	507
6	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 2020, 14, 889-919.	4.2	422
7	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 362-373.	8.1	411
8	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
9	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	12.1	195
10	Apoptosis: why and how does it occur in biology?. Cell Biochemistry and Function, 2011, 29, 468-480.	2.9	180
11	Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2007, 13, 837.	3.3	165
12	Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2010, 40, 887-892.	3.4	159
13	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	8.1	135
14	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	3.7	114
15	Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2011, 46, 91-97.	1.5	107
16	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1625-1633.e1.	4.4	107
17	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	7.3	102
18	Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism: Clinical and Experimental, 2010, 59, 1327-1330.	3.4	93

#	Article	IF	Citations
19	Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Atherosclerosis, 2010, 211, 182-186.	0.8	84
20	Obesity-Associated Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2014, 18, 19-31.	2.1	75
21	Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scandinavian Journal of Gastroenterology, 2015, 50, 341-346.	1.5	74
22	Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 2013, 43, 100-107.	2.3	72
23	Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori. Journal of Medicinal Food, 2011, 14, 344-347.	1.5	70
24	Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis, 2014, 237, 490-493.	0.8	67
25	Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2011, 60, 544-549.	3.4	61
26	Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 2009, 42, 802-807.	1.9	58
27	Serum fetuin A/Î±2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Annals of Clinical Biochemistry, 2010, 47, 549-553.	1.6	56
28	Clinical Value of the Malnutrition-Inflammation-Atherosclerosis Syndrome for Long-Term Prediction of Cardiovascular Mortality in Patients with End-Stage Renal Disease: A 5-Year Prospective Study. Nephron Clinical Practice, 2008, 108, c99-c105.	2.3	53
29	Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis, 2011, 217, 125-129.	0.8	53
30	Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gut and Liver, 2020, 14, 486-491.	2.9	51
31	Liver disease and malnutrition. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 619-629.	2.4	50
32	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	4.4	49
33	Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. Journal of Clinical and Translational Hepatology, 2022, 10, 329-338.	1.4	49
34	NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?. Seminars in Liver Disease, 2012, 32, 014-021.	3.6	45
35	Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2009, 15, 4387.	3.3	44
36	Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2011, 9, 287-290.	1.3	44

#	Article	IF	Citations
37	Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clinical Biochemistry, 2012, 45, 655-658.	1.9	43
38	A comparison of FibroMeterâ„¢ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2014, 49, 1343-1348.	1.5	43
39	Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. European Journal of Gastroenterology and Hepatology, 2019, 31, 43-46.	1.6	43
40	Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. European Journal of Gastroenterology and Hepatology, 2009, 21, 1247-1251.	1.6	41
41	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetologica, 2020, 57, 613-618.	2.5	41
42	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Review of Gastroenterology and Hepatology, 2021, 15, 345-352.	3.0	41
43	Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2012, 24, 255-261.	1.6	40
44	Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 631-636.	1.2	39
45	Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 541-546.	1.2	38
46	Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. European Journal of Clinical Investigation, 2012, 42, 411-418.	3.4	37
47	Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. European Journal of Gastroenterology and Hepatology, 2020, 32, 1352-1357.	1.6	37
48	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 137-141.	1.6	36
49	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, 98-103.	1.6	33
50	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. European Journal of Gastroenterology and Hepatology, 2013, 25, 1330-1334.	1.6	32
51	Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 427-431.	0.9	32
52	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scandinavian Journal of Gastroenterology, 2014, 49, 611-616.	1.5	31
53	Non-alcoholic fatty liver disease: A growing public health problem in Turkey. Turkish Journal of Gastroenterology, 2019, 30, 865-871.	1.1	30
54	Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease. Gut and Liver, 2014, 8, 313-317.	2.9	28

#	Article	IF	Citations
55	Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clinical Biochemistry, 2008, 41, 1055-1058.	1.9	27
56	Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism: Clinical and Experimental, 2010, 59, 64-69.	3.4	25
57	The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. European Journal of Gastroenterology and Hepatology, 2020, 32, 642-649.	1.6	24
58	Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Disease Markers, 2011, 31, 205-210.	1.3	24
59	Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turkish Journal of Gastroenterology, 2019, 30, 892-898.	1.1	24
60	The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 411-417.	1.6	23
61	Nonalcoholic Fatty Liver Disease: A Nutritional Approach. Metabolic Syndrome and Related Disorders, 2012, 10, 161-166.	1.3	22
62	Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovascular Therapeutics, 2015, 33, 294-299.	2.5	22
63	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2013, 45, 58-62.	0.9	21
64	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1149-1153.	1.6	21
65	Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?. World Journal of Hepatology, 2012, 4, 332.	2.0	20
66	Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. Turkish Journal of Gastroenterology, 2019, 30, 266-270.	1.1	20
67	Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Medical Science Monitor, 2009, 15, CR189-93.	1.1	20
68	Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2012, 47, 1488-1493.	1.5	19
69	A â€œBiomarker Biopsyâ€•for the Diagnosis of NASH: Promises from CK-18 Fragments. Obesity Surgery, 2008, 18, 1507-1508.	2.1	18
70	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. European Journal of Gastroenterology and Hepatology, 2016, 28, 1264-1267.	1.6	18
71	Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Diabetes and Its Complications, 2014, 28, 328-331.	2.3	17
72	Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology, 2009, 49, 697-697.	7.3	16

#	Article	IF	Citations
73	Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clinica Chimica Acta, 2012, 414, 154-157.	1.1	16
74	Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scandinavian Journal of Gastroenterology, 2009, 44, 1471-1476.	1.5	14
75	Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 391-391.	7.3	14
76	Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clinica Chimica Acta, 2011, 412, 2296-2299.	1.1	14
77	Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. Archives of Medical Research, 2011, 42, 38-43.	3.3	14
78	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. EClinicalMedicine, 2021, 41, 101145.	7.1	14
79	Cytokeratins in hepatitis. Clinica Chimica Acta, 2011, 412, 2031-2036.	1.1	13
80	Serum zinc-Î±2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. Clinical Chemistry and Laboratory Medicine, 2011, 49, 93-7.	2.3	13
81	Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clinica Chimica Acta, 2010, 411, 2029-2032.	1.1	12
82	Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clinica Chimica Acta, 2012, 413, 1190-1193.	1.1	12
83	Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study. European Journal of Gastroenterology and Hepatology, 2020, 32, 54-57.	1.6	11
84	Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials. Current Drug Targets, 2013, 14, 1357-1366.	2.1	11
85	Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. Coronary Artery Disease, 2009, 20, 494-498.	0.7	10
86	Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 2011, 44, 955-958.	1.9	10
87	Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori, 2013, 99, 10-16.	1.1	10
88	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 667-671.	1.6	10
89	Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients. Annales D'Endocrinologie, 2020, 81, 493-499.	1.4	9
90	Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?. World Journal of Gastroenterology, 2009, 15, 4346.	3.3	9

#	Article	IF	Citations
91	Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. Abdominal Radiology, 2016, 41, 1505-1510.	2.1	8
92	Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones, 2019, 18, 463-475.	1.9	8
93	Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 8096.	3.3	8
94	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 1292-1295.	1.6	7
95	Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study. International Journal of Clinical Practice, 2021, 75, e14363.	1.7	7
96	Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Disease Markers, 2012, 33, 77-83.	1.3	7
97	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€"Occamâ€™s razor applied to advanced fibrosis screening. Alimentary Pharmacology and Therapeutics, 2020, 52, 1759-1760.	3.7	7
98	Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning. Gastroenterology Research and Practice, 2016, 2016, 1-5.	1.5	5
99	The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 597-600.	1.6	5
100	Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	5
101	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
102	The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. Hepatology, 2009, 49, 1056-1057.	7.3	4
103	Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments. Biomarkers in Medicine, 2010, 4, 743-745.	1.4	4
104	Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. , 2021, 32, 661-666.		4
105	The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. Journal of Gastroenterology, 2010, 45, 782-783.	5.1	3
106	Is M65 really better than M30 as a biomarker of hepatic fibrosis?. Hepatology, 2012, 55, 654-654.	7.3	2
107	Hepatic fibrosis â€" and not steatosis â€" is the main determinant of arterial stiffness in non-alcoholic fatty liver disease. Atherosclerosis, 2019, 290, 222-223.	0.8	2
108	Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population. Alimentary Pharmacology and Therapeutics, 2020, 51, 669-670.	3.7	2

#	Article	IF	Citations
109	Non-alcoholic Fatty Liver Disease: A Global Public Health Issue. , 2020, , 321-333.		2
110	â€œDefragmentingâ€•the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18. Hepatology, 2009, 50, 990-991.	7.3	1
111	Reply to Aydin et al: â€œTo what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?â€• Metabolism: Clinical and Experimental, 2011, 60, e2.	3.4	1
112	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	3.4	1
113	NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?. Angiology, 2020, 71, 83-84.	1.8	1
114	Evaluation of spleen stiffness in healthy population: a vibration-controlled transient elastography study. Journal of Health Sciences and Medicine, 2022, 5, 689-692.	0.1	1
115	Commentary on â€œCytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Diseaseâ€• Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 371-371.	1.8	0
116	Molecular signatures of nonalcoholic fatty liver disease: The present and future. Hepatology, 2010, 51, 1866-1866.	7.3	0
117	Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats. Obesity Surgery, 2011, 21, 1316-1317.	2.1	0
118	Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter. European Journal of Gastroenterology and Hepatology, 2019, 31, 1601-1602.	1.6	0
119	Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study. Turkish Journal of Gastroenterology, 2020, 31, 676-680.	1.1	0